Lista de obras - Suzanne L Topalian - Dominio Público Uruguay

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

artículo científico publicado en 2002

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

artículo científico publicado en 2005

Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines

artículo científico publicado en 2006

Antagonists of PD-1 and PD-L1 in Cancer Treatment

artículo científico publicado en 2015

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy

artículo científico publicado en 2017

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

artículo científico publicado en 2005

Balance and imbalance in the immune system: life on the edge

artículo científico publicado en 2014

Cancer immunotherapy comes of age

artículo científico publicado en 2011

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

artículo científico publicado en 2002

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

artículo científico publicado en 2003

Cancer regression in patients after transfer of genetically engineered lymphocytes

artículo científico publicado en 2006

Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma

artículo científico publicado en 2003

Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas

artículo científico publicado en 2020

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

artículo científico publicado en 2012

Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1

artículo científico publicado en 2011

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

artículo científico publicado en 2005

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

artículo científico publicado en 2015

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

artículo científico publicado en 2006

Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma

artículo científico publicado en 2006

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy

artículo científico publicado en 2009

Immune checkpoint blockade: a common denominator approach to cancer therapy

artículo científico publicado en 2015

Immunization of HLA-A0201 and/or HLA-DPbeta104 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen

artículo científico publicado en 2004

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens

artículo científico publicado en 2003

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

artículo científico publicado en 2003

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

artículo científico publicado en 2006

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

artículo científico publicado en 2007

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

artículo científico publicado en 2016

Mechanisms regulating PD-L1 expression on tumor and immune cells

scientific article published on 15 November 2019

Meeting report: The future of preclinical mouse models in melanoma treatment is now.

artículo científico publicado en 2013

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Neoadjuvant Therapy for Melanoma: A US Food and Drug Administration - Melanoma Research Alliance Public Workshop

artículo científico publicado en 2020

Neoadjuvant checkpoint blockade for cancer immunotherapy

artículo científico publicado en 2020

Opportunities and challenges in the development of experimental drug combinations for cancer

artículo científico publicado en 2011

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2015

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

artículo científico publicado en 2016

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

scientific article published on 31 October 2019

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma

artículo científico publicado en 2002

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

artículo científico publicado en 2003

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma

artículo científico publicado en 2003

Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme.

artículo científico publicado en 2002

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

artículo científico publicado en 2012

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

artículo científico publicado en 2015

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

artículo científico publicado en 2012

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule

scientific article published on 21 June 2016

Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells

artículo científico publicado en 2010

Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor

artículo científico publicado en 2007

Structural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by Vα CDR3

artículo científico publicado en 2012

Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity

artículo científico publicado en 2013

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

artículo científico publicado en 2015

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

artículo científico publicado en 2012

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy

artículo científico publicado en 2017

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma

artículo científico publicado en 2016

The genetic evolution of treatment-resistant cutaneous, acral and uveal melanomas

artículo científico publicado en 2020

Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.

artículo científico publicado en 2017

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

artículo científico publicado en 2005

Lista de obras de Suzanne L Topalian

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines

Antagonists of PD-1 and PD-L1 in Cancer Treatment

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

Balance and imbalance in the immune system: life on the edge

Cancer immunotherapy comes of age

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Cancer regression in patients after transfer of genetically engineered lymphocytes

Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma

Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy

Immune checkpoint blockade: a common denominator approach to cancer therapy

Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Mechanisms regulating PD-L1 expression on tumor and immune cells

Meeting report: The future of preclinical mouse models in melanoma treatment is now.

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

Neoadjuvant Therapy for Melanoma: A US Food and Drug Administration - Melanoma Research Alliance Public Workshop

Neoadjuvant checkpoint blockade for cancer immunotherapy

Opportunities and challenges in the development of experimental drug combinations for cancer

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma

Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme.

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule

Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells

Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor

Structural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by Vα CDR3

Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma

The genetic evolution of treatment-resistant cutaneous, acral and uveal melanomas

Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

Immunization of HLA-A0201 and/or HLA-DPbeta104 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen